Phenotypic profiling and prognostic significance of immune infiltrates in esophageal squamous cell carcinoma

References

• Hong Y, Ding ZY. PD-1 inhibitors in the advanced esophageal cancer. Front Pharmacol. 2019;10:1418. doi:10.3389/fphar.2019.01418.
   PubMed Web of Science ®Google Scholar
• Wen J, Wang G, Xie X, Lin G, Yang H, Luo K, Liu Q, Ling Y, Xie X, Lin P, et al. Prognostic value of a Four-miRNA signature in patients with lymph node positive locoregional esophageal squamous cell carcinoma undergoing complete surgical resection. Ann Surg. 2019 Apr 30. doi:10.1097/SLA.0000000000003369.
   Web of Science ®Google Scholar
• Wen J, Luo K, Liu H, Liu S, Lin G, Hu Y, Zhang X, Wang G, Chen Y, Chen Z, et al. MiRNA expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neoadjuvant chemoradiotherapy. Ann Surg. 2016 May;263(5):942–13. doi:10.1097/SLA.0000000000001489.
   PubMed Web of Science ®Google Scholar
• Wen J, Yang H, Liu MZ, Luo KJ, Liu H, Hu Y, Zhang X, Lai RC, Lin T, Wang HY, et al. Gene expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neo-chemoradiotherapy. Ann Oncol. 2014 Sep;25(9):1769–1774. doi:10.1093/annonc/mdu201.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646–674. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Yue Y, Lian J, Wang T, Luo C, Yuan Y, Qin G, Zhang B, Zhang Y. Interleukin-33-nuclear factor-kappaB-CCL2 signaling pathway promotes progression of esophageal squamous cell carcinoma by directing regulatory T cells. Cancer Sci. 2020 Mar;111(3):795–806. doi:10.1111/cas.14293.
   PubMed Web of Science ®Google Scholar
• Yang H, Zhang Q, Xu M, Wang L, Chen X, Feng Y, Li Y, Zhang X, Cui W, Jia X, et al. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis. Mol Cancer. 2020 Feb 27;19(1):41. doi:10.1186/s12943-020-01165-x.
   PubMed Web of Science ®Google Scholar
• Bruno A, Ferlazzo G, Albini A, Noonan DM. A think tank of TINK/TANKs: tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis. J Natl Cancer Inst. 2014 Aug;106(8):dju200. doi:10.1093/jnci/dju200.
   PubMedGoogle Scholar
• Huang TX, Fu L. The immune landscape of esophageal cancer. Cancer Commun (Lond). 2019 Nov 26;39(1):79. doi:10.1186/s40880-019-0427-z.
   PubMed Web of Science ®Google Scholar
• Melaiu O, Lucarini V, Cifaldi L, Fruci D. Influence of the tumor microenvironment on NK cell function in solid tumors. Front Immunol. 2019;10:3038. doi:10.3389/fimmu.2019.03038.
   PubMed Web of Science ®Google Scholar
• Fu C. Dendritic Cells and CD8 T cell immunity in tumor microenvironment. Front Immunol. 2018;9:3059. doi:10.3389/fimmu.2018.03059.
   PubMed Web of Science ®Google Scholar
• Farhood B, Najafi M, Mortezaee K. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol. 2019 Jun;234(6):8509–8521. doi:10.1002/jcp.27782.
   PubMed Web of Science ®Google Scholar
• Chraa D, Naim A, Olive D, Badou A. T lymphocyte subsets in cancer immunity: friends or foes. J Leukoc Biol. 2019 Feb;105(2):243–255. doi:10.1002/jlb.Mr0318-097r.
   PubMed Web of Science ®Google Scholar
• Reading JL, Galvez-Cancino F, Swanton C, Lladser A, Peggs KS, Quezada SA. The function and dysfunction of memory CD8(+) T cells in tumor immunity. Immunol Rev. 2018 May;283(1):194–212. doi:10.1111/imr.12657.
   PubMed Web of Science ®Google Scholar
• Oliva S, Troia R, D’Agostino M, Boccadoro M, Gay F. Promises and pitfalls in the use of PD-1/PD-L1 inhibitors in multiple myeloma. Front Immunol. 2018 Nov 27;9(1664–3224 (Electronic)):2749. doi:10.3389/fimmu.2018.02749.
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010 Aug 15;127(4):759–767. doi:10.1002/ijc.25429.
   PubMed Web of Science ®Google Scholar
• DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019 Jun;19(6):369–382. doi:10.1038/s41577-019-0127-6.
   PubMed Web of Science ®Google Scholar
• Miyashita T, Tajima H, Shah FA, Oshima M, Makino I, Nakagawara H, Kitagawa H, Fujimura T, Harmon JW, Ohta T, et al. Impact of inflammation-metaplasia-adenocarcinoma sequence and inflammatory microenvironment in esophageal carcinogenesis using surgical rat models. Ann Surg Oncol. 2014 Jun;21(6):2012–2019. doi:10.1245/s10434-014-3537-5.
   PubMed Web of Science ®Google Scholar
• Wang W, Chen D, Zhao Y, Zhao T, Wen J, Mao Y, Chen C, Sang Y, Zhang Y, Chen Y, et al. Characterization of LAG-3, CTLA-4, and CD8+ TIL density and their joint influence on the prognosis of patients with esophageal squamous cell carcinoma. Ann Transl Med. 2019 Dec;7(23):776. doi:10.21037/atm.2019.11.38.
   PubMed Web of Science ®Google Scholar
• Wang J, Jia Y, Wang N, Zhang X, Tan B, Zhang G, Cheng Y. The clinical significance of tumor-infiltrating neutrophils and neutrophil-to-CD8+ lymphocyte ratio in patients with resectable esophageal squamous cell carcinoma. J Transl Med. 2014 Jan 7;12:7. doi:10.1186/1479-5876-12-7.
   PubMed Web of Science ®Google Scholar
• Chen K, Zhu Z, Zhang N, Cheng G, Zhang F, Jin J, Wu J, Ying L, Mao W, Su D, et al. Tumor-infiltrating CD4+ lymphocytes predict a favorable survival in patients with operable esophageal squamous cell carcinoma. Med Sci Monit. 2017 Sep 26;23:4619–4632. doi:10.12659/msm.904154.
   PubMed Web of Science ®Google Scholar
• Hao J, Li M, Zhang T, Yu H, Liu Y, Xue Y, An R, Wang S. Prognostic value of tumor-infiltrating lymphocytes differs depending on lymphocyte subsets in esophageal squamous cell carcinoma: an updated meta-analysis. Front Oncol. 2020;10(2234–943X (Print)):614. doi:10.3389/fonc.2020.00614.
   PubMed Web of Science ®Google Scholar
• Yoshioka T, Miyamoto M, Cho Y, Ishikawa K, Tsuchikawa T, Kadoya M, Li L, Mishra R, Ichinokawa K, Shoji Y, et al. Infiltrating regulatory T cell numbers is not a factor to predict patient’s survival in oesophageal squamous cell carcinoma. Br J Cancer. 2008 Apr 8;98(7):1258–1263. doi:10.1038/sj.bjc.6604294.
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M, Fredriksen T, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity. 2016 Mar 15;44(3):698–711. doi:10.1016/j.immuni.2016.02.025.
   PubMed Web of Science ®Google Scholar
• Savas P, Virassamy B, Ye C, Salim A, Mintoff CP, Caramia F, Salgado R, Byrne DJ, Teo ZL, Dushyanthen S, et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat Med. 2018 Jul;24(7):986–993. doi:10.1038/s41591-018-0078-7.
   PubMed Web of Science ®Google Scholar
• Enomoto K, Sho M, Wakatsuki K, Takayama T, Matsumoto S, Nakamura S, Akahori T, Tanaka T, Migita K, Ito M, et al. Prognostic importance of tumour-infiltrating memory T cells in oesophageal squamous cell carcinoma. Clin Exp Immunol. 2012 May;168(2):186–191. doi:10.1111/j.1365-2249.2012.04565.x.
   PubMed Web of Science ®Google Scholar
• Yagi T, Baba Y, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, Watanabe M, Baba H. PD-L1 expression, tumor-infiltrating lymphocytes, and clinical outcome in patients with surgically resected esophageal cancer. Ann Surg. 2019 Mar;269(3):471–478. doi:10.1097/SLA.0000000000002616.
   PubMed Web of Science ®Google Scholar
• Chen K, Cheng G, Zhang F, Zhang N, Li D, Jin J, Wu J, Ying L, Mao W, Su D, et al. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. Oncotarget. 2016 May 24;7(21):30772–30780. doi:10.18632/oncotarget.8956.
   PubMedGoogle Scholar
• Jiang D, Song Q, Wang H, Huang J, Wang H, Hou J, Li X, Xu Y, Sujie A, Zeng H, et al. Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma. Oncotarget. 2017 Jan 31;8(5):8315–8329. doi:10.18632/oncotarget.14174.
   PubMedGoogle Scholar
• Stack EC, Wang C, Roman KA, Hoyt CC. Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. Methods. 2014 Nov;70(1):46–58. doi:10.1016/j.ymeth.2014.08.016.
   PubMed Web of Science ®Google Scholar
• Wen J, Luo KJ, Hu Y, Yang H, Fu JH. Metastatic lymph node CHIP expression is a potential prognostic marker for resected esophageal squamous cell carcinoma patients. Ann Surg Oncol. 2013 May;20(5):1668–1675. doi:10.1245/s10434-012-2733-4.
   PubMed Web of Science ®Google Scholar
• Baddeley A, Rubak E, Turner R. Spatial point patterns: methodology and applications with R. CRC Press;  Boca Raton, Florida, USA. 2015.
   Google Scholar
• Yagi T, Baba Y, Okadome K, Kiyozumi Y, Hiyoshi Y, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, Watanabe M, et al. Tumour-associated macrophages are associated with poor prognosis and programmed death ligand 1 expression in oesophageal cancer. Eur J Cancer. 2019 Apr;111(1879–0852 (Electronic)):38–49. doi:10.1016/j.ejca.2019.01.018.
   PubMed Web of Science ®Google Scholar
• Golubovskaya V, Wu L. Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy. Cancers (Basel). 2016 Mar 15;8(3):36. doi:10.3390/cancers8030036.
   PubMed Web of Science ®Google Scholar
• Nagl S, Haas M, Lahmer G, Büttner-Herold M, Grabenbauer GG, Fietkau R, Distel LV. Cell-to-cell distances between tumor-infiltrating inflammatory cells have the potential to distinguish functionally active from suppressed inflammatory cells. Oncoimmunology. 2016 May;5(5):e1127494. doi:10.1080/2162402X.2015.1127494.
   PubMed Web of Science ®Google Scholar
• Galon J, Pages F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012 Oct 3;10(1479–5876 (Electronic)):205. doi:10.1186/1479-5876-10-205.
   PubMed Web of Science ®Google Scholar
• Lin EW, Karakasheva TA, Hicks PD, Bass AJ, Rustgi AK. The tumor microenvironment in esophageal cancer. Oncogene. 2016 Oct 13;35(41):5337–5349. doi:10.1038/onc.2016.34.
   PubMed Web of Science ®Google Scholar
• Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol. 2014 Jan;232(2):199–209. doi:10.1002/path.4287.
   PubMed Web of Science ®Google Scholar
• Tang H, Liang Y, Anders RA, Taube JM, Qiu X, Mulgaonkar A, Liu X, Harrington SM, Guo J, Xin Y, et al. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin Invest. 2018 Feb 1;128(2):580–588. doi:10.1172/JCI96061.
   PubMed Web of Science ®Google Scholar
• Gardner A, Ruffell B. Dendritic cells and cancer immunity. Trends Immunol. 2016 Dec;37(12):855–865. doi:10.1016/j.it.2016.09.006.
   PubMed Web of Science ®Google Scholar
• Allie SR, Zhang W, Fuse S, Usherwood EJ. Programmed death 1 regulates development of central memory CD8 T cells after acute viral infection. J Immunol. 2011 Jun 1;186(11):6280–6286. doi:10.4049/jimmunol.1003870.
   PubMed Web of Science ®Google Scholar
• Gibbons RM, Liu X, Pulko V, Pulko V, Harrington SM, Krco CJ, Kwon ED, Dong H. B7-H1 limits the entry of effector CD8(+) T cells to the memory pool by upregulating Bim. Oncoimmunology. 2012 Oct 1;1(7):1061–1073. doi:10.4161/onci.20850.
   PubMed Web of Science ®Google Scholar
• Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009 Dec 21;206(13):3015–3029. doi:10.1084/jem.20090847.
   PubMed Web of Science ®Google Scholar
• Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019 Mar;18(3):197–218. doi:10.1038/s41573-018-0007-y.
   PubMed Web of Science ®Google Scholar
• Angell H, Galon J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol. 2013 Apr;25(2):261–267. doi:10.1016/j.coi.2013.03.004.
   PubMed Web of Science ®Google Scholar
• Wu C, Lin J, Weng Y, Zeng D-N, Xu J, Luo S, Xu L, Liu M, Hua Q, Liu C-Q, et al. Myeloid signature reveals immune contexture and predicts the prognosis of hepatocellular carcinoma. J Clin Invest. 2020 Sep 1;130(9):4679–4693. doi:10.1172/jci135048.
   PubMed Web of Science ®Google Scholar